华软科技(002453) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥403,454,656.69, a decrease of 28.48% compared to ¥564,104,201.07 in the same period last year[9]. - The net profit attributable to shareholders was -¥11,164,862.70, representing a decline of 338.52% from ¥4,680,858.99 in the previous year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥16,532,584.64, a decrease of 501.52% compared to ¥4,117,458.90 last year[9]. - The net profit for the current period is a loss of ¥10,000,568.67, compared to a net profit of ¥9,051,371.16 in the previous period[70]. - The company reported a gross loss of ¥13,658,422.65 in operating profit, contrasting with a profit of ¥10,150,708.80 in the previous period[70]. - The company reported a net loss of ¥370,959,154.96, compared to a loss of ¥357,957,362.62 in the previous period[56]. - The net profit for the period was -3,242,993.56, an improvement from -4,842,564.28 in the previous period, indicating a reduction in losses[78]. - Total comprehensive income for the period was -3,242,993.56, compared to -4,842,564.28 in the previous period, reflecting a similar trend[80]. Cash Flow - The net cash flow from operating activities was ¥7,554,538.40, improving from -¥14,227,913.63 in the same period last year[9]. - Operating cash flow turned positive at ¥7,554,538.40, a significant improvement from a negative cash flow of ¥14,227,913.63 in the previous period[24]. - Cash flow from operating activities generated a net inflow of 7,554,538.40, a significant recovery from -14,227,913.63 in the previous period[81]. - Cash flow from investing activities resulted in a net outflow of -121,990,978.74, worsening from -54,929,951.67 in the previous period[84]. - Cash flow from financing activities generated a net inflow of 118,162,903.25, compared to 6,615,201.16 in the previous period, reflecting improved financing conditions[87]. - The net cash flow from operating activities was ¥10,057,754.97, a significant improvement compared to the previous period's net cash flow of -¥23,383,310.23[88]. - The net cash flow from investment activities was -¥162,288,190.00, worsening from -¥42,437,153.75 in the prior period[91]. - The net cash flow from financing activities was ¥139,804,171.53, up from ¥104,106,732.66 in the prior period[91]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,159,009,618.47, an increase of 18.12% from ¥1,827,871,759.04 at the end of the previous year[9]. - The total liabilities reached ¥1,482,415,004.10, up from ¥1,139,658,906.91, marking an increase of around 30.1%[56]. - Current liabilities rose to ¥1,167,696,382.42, compared to ¥949,031,217.01, indicating an increase of about 23.1%[53]. - Long-term borrowings increased significantly to ¥302,435,259.02 from ¥178,240,003.34, reflecting a growth of approximately 69.7%[53]. - The total non-current assets amounted to ¥831,924,210.18, slightly down from ¥832,478,905.31[60]. - The total amount of accounts payable is CNY 15.59 million[100]. - The company has a total of CNY 361.58 million in other payables[100]. Shareholder Information - The net assets attributable to shareholders were ¥578,042,746.76, a decrease of 2.17% from ¥590,852,839.60 at the end of the previous year[9]. - The company had a total of 40,533 common shareholders at the end of the reporting period[14]. - The company's total equity decreased to ¥676,594,614.37 from ¥688,212,852.13, a decline of about 1.9%[56]. - The total equity is reported at ¥698,710,876.82, slightly down from ¥701,953,870.38 in the previous period[63]. Operational Changes - The company received government subsidies amounting to ¥1,505,557.79 during the reporting period[9]. - The company’s subsidiary, Fujian Lifek Pharmaceutical Co., Ltd., has started producing and selling medical masks, protective clothing, and disinfectant alcohol in response to local government requirements during the pandemic[29]. - The company plans to gradually shut down its wholly-owned subsidiaries, Nantong Nabaiyuan Chemical Co., Ltd. and Zhenjiang Runport Chemical Co., Ltd.[29]. - The company signed a leasing agreement with Suzhou Tianma Pharmaceutical Co., Ltd. for its incinerator assets, with an annual rent of ¥7.91 million, effective until December 31, 2022[32]. - The company appointed Zhang Jie as the new president and made several changes to its senior management team on March 12, 2020[29]. Inventory and Prepayments - Cash and cash equivalents increased by 60.21% to ¥142,998,464.80 due to an increase in acceptance bill margin[24]. - Prepayments surged by 619.01% to ¥126,915,315.79 as a result of increased advance payments for goods[24]. - Inventory rose by 47.43% to ¥144,756,398.46, indicating an increase in stock of goods[24]. - The company’s inventory increased to approximately ¥144.76 million from ¥98.19 million, representing a growth of about 47%[47]. Research and Development - Research and development expenses decreased by 70.52% to ¥1,044,364.45 due to a reduction in the scope of consolidation[24]. - Research and development expenses for the current period are ¥1,044,364.45, significantly reduced from ¥3,543,023.70 in the previous period[67].